康希诺生物股份公司 自愿披露关于冻干b型流感嗜血杆菌结合疫苗 启动I期临床试验并完成首例受试者入组的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 康希诺生物股份公司（以下简称"公司"）的冻干b型流感嗜血杆菌结合疫 苗（以下简称"Hib疫苗"）于近日正式启动I期临床试验，并完成首例受试者入 组。 一、产品基本情况 公司正在研发以组分百白破为基础的联合疫苗，Hib 疫苗为其中的组成部 分，作为未获批上市的单苗需累积一定的临床数据，以支持未来以组分百白破为 基础的联合疫苗的注册申报。 证券代码：688185 证券简称：康希诺 公告编号：2024-047 流感嗜血杆菌为革兰阴性杆菌，是儿童急性下呼吸道感染最主要的病原菌之 一，分为有荚膜型和无荚膜型，两者均可引发感染。无荚膜型菌株常可引发中耳 炎和鼻窦炎等疾病。主要由鼻咽部定植细菌在邻近部位传播所致；继发于血流侵 袭的感染通常由荚膜型菌株引起。有荚膜的菌株根据荚膜多糖的化学成分来进行 分类，迄今已发现 6 种血清型，其中，约 95%的侵袭性流感嗜血杆菌疾病由 b 型引起。 ...

FF301 本月底法定/註冊股本總額： RMB 247,449,899 致：香港交易及結算所有限公司 FF301 II. 已發行股份及/或庫存股份變動 | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 688185 | 說明 | | A 股 (上海證券交易所科創版) | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 114,778,999 | RMB | | 1 RMB | | 114,778,999 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 114,778,999 | RMB | | 1 RMB | | 114,778,999 | | | | 呈交日期: 2024年11月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | ...

Group 1: Financial Performance - The company's revenue for the first three quarters of 2024 reached 567 million CNY, a year-on-year increase of 222.88%. Excluding the impact of estimated returns of COVID-19 vaccines from the previous year, the revenue growth is 36.85% [2] - In Q3 2024, the single-quarter revenue was 264 million CNY, reflecting a year-on-year growth of 76.09% [2] - The net loss for the first three quarters of 2024 narrowed by over 80%, with a net profit attributable to shareholders of approximately 2.96 million CNY in Q3 [2] Group 2: Product Development and Sales - Sales of the meningococcal vaccine product reached 516 million CNY in the first three quarters of 2024, a 39.07% increase compared to the same period last year [3] - The company is advancing the commercialization of its high-end quadrivalent meningococcal vaccine, aiming to enhance market penetration and share [3] - The PCV13 i vaccine's new drug application was accepted by the regulatory authority in February 2024, with ongoing communication regarding clinical trial results and market strategies [4] Group 3: Research and Development - R&D expenses for the first three quarters of 2024 totaled 272 million CNY, accounting for a year-on-year decrease of 63 percentage points relative to total revenue [3] - The company is focusing on optimizing resource allocation to enhance differentiated R&D efforts [3] - The PBPV vaccine has completed Phase I clinical trials with positive preliminary results, indicating good safety and potential broad-spectrum efficacy [5] Group 4: Funding and Strategic Partnerships - In October 2024, the company received a grant of 17 million USD from the Gates Foundation to support the research and development of the recombinant poliovirus vaccine [7] - The innovative vaccine does not rely on live viruses, differentiating it from traditional polio vaccines, and is currently undergoing clinical trials in Australia and Indonesia [7] Group 5: Market Strategy and Future Outlook - The company is exploring the commercialization of its CDMO business, which currently generates limited revenue but leverages its advanced technology platform [6] - The transition of COVID-19 vaccines from public insurance to self-pay will require adjustments based on local health authority feedback [6] - The company aims to maximize the advantages of its technology platforms to achieve positive financial impacts in the future [6]

Revenue and Profitability - Total revenue for the nine months ended September 30, 2024, was RMB 263,646,520.16, representing a 76.09% increase compared to the same period last year[4] - Net profit attributable to shareholders for the reporting period was RMB 2,964,467.27, a significant recovery from a loss of RMB 222,409,418.57 in the previous year[4] - Basic earnings per share for the current period was RMB 0.01, compared to a loss of RMB 0.90 per share in the same period last year[5] - The company's operating revenue for the year-to-date period increased by 222.88%, reaching 238,757,612.38 CNY, with a year-on-year growth of 36.85% after excluding the impact of COVID-19 vaccine returns[9] - Sales revenue from the meningococcal vaccine product reached 516,153,650.93 CNY, representing a year-on-year increase of 39.07%[9] - The net loss attributable to shareholders of the listed company for the first three quarters was 222,409,418.57 CNY, significantly reduced by 762,620,235.90 CNY compared to the previous year[9] - The company achieved a single-quarter net profit attributable to shareholders of 2,964,467.27 CNY in the third quarter[9] - Total revenue for the first three quarters of 2024 was a loss of 227,196,536.24 RMB, compared to a loss of 1,454,919,925.84 RMB in the same period of 2023, indicating a significant improvement[23] - Operating profit for the first three quarters of 2024 was a loss of 222,830,476.31 RMB, compared to a loss of 1,415,383,868.45 RMB in the same period of 2023, reflecting a reduction in operational losses[23] - Total comprehensive income attributable to the parent company for the first three quarters of 2024 was a loss of (226,815,781.51) RMB, compared to a loss of (1,454,797,112.46) RMB in the same period of 2023[25] Assets and Liabilities - Total assets as of September 30, 2024, were RMB 7,989,566,970.77, a decrease of 14.26% from RMB 9,318,769,372.66 at the end of the previous year[5] - As of September 30, 2024, total current assets were RMB 4,369,254,431.78, down from RMB 5,180,827,776.61 at the end of 2023, reflecting a decline of about 16%[18] - Total non-current assets decreased to RMB 3,620,312,538.99 from RMB 4,137,941,596.05, representing a reduction of approximately 12.5%[19] - Total liabilities as of September 30, 2024, were RMB 2,926,151,613.50, down from RMB 4,031,354,058.75, indicating a decrease of about 27%[20] - The company's total assets decreased to RMB 7,989,566,970.77 from RMB 9,318,769,372.66, reflecting a decline of approximately 14.2%[21] - The company's retained earnings showed a negative balance of RMB (1,780,823,276.18) as of September 30, 2024, compared to RMB (1,558,413,857.61) at the end of 2023[21] - Cash and cash equivalents decreased to RMB 1,364,455,953.58 from RMB 2,821,595,241.10, a decline of approximately 52%[18] - Short-term borrowings were reduced to RMB 596,881,991.30 from RMB 854,082,887.35, indicating a decrease of about 30%[20] Research and Development - Research and development expenses totaled RMB 107,918,795.43, a decrease of 23.18% compared to the same period last year[5] - The ratio of R&D expenses to total revenue was 40.93%, down 52.89 percentage points from the previous year[5] - Research and development expenses as a percentage of operating revenue decreased by 210.45 percentage points compared to the previous year[12] - Research and development expenses for the first three quarters of 2024 amounted to RMB 272,272,224.71, a decrease of approximately 41% compared to RMB 461,673,523.32 in 2023[22] Cash Flow - The company reported a net cash flow from operating activities of RMB (287,414,483.35), indicating ongoing challenges in cash generation[4] - Cash flow from operating activities for the first three quarters of 2024 was a net outflow of 287,414,483.35 RMB, an improvement from a net outflow of 748,974,021.75 RMB in the same period of 2023[28] - The company’s cash outflow for operating activities totaled 897,365,298.94 RMB in the first three quarters of 2024, down from 1,364,783,068.46 RMB in the same period of 2023, indicating improved cash management[28] - Cash inflow from investment activities for the first three quarters of 2024 was 9,594,480,245.55 RMB, compared to 6,640,825,701.63 RMB in the same period of 2023, showing a substantial increase[28] - Cash inflow from financing activities for the first three quarters of 2024 was approximately $709.2 million, a decrease of 48.5% compared to $1.32 billion in the same period of 2023[29] - Cash outflow for debt repayment in the first three quarters of 2024 was approximately $884.9 million, down 37.1% from $1.41 billion in the first three quarters of 2023[29] - Net cash flow from financing activities for the first three quarters of 2024 was negative $232.9 million, compared to negative $131.3 million in the same period of 2023[29] - The ending cash and cash equivalents balance for the first three quarters of 2024 was approximately $868.9 million, a decrease of 63.0% from $2.35 billion at the end of the same period in 2023[29] - The impact of exchange rate changes on cash and cash equivalents was negative $882.2 thousand in the first three quarters of 2024, contrasting with a positive impact of $51.8 million in the same period of 2023[29] Government Subsidies and Non-Recurring Items - The company received government subsidies amounting to RMB 14,565,011.91, which are not included in non-recurring gains and losses[6] - The total non-recurring gains and losses for the current period amounted to RMB 9,686,646.95, compared to RMB 38,838,797.88 for the previous period[7] - Other comprehensive income after tax for the first three quarters of 2024 was 380,754.73 RMB, significantly higher than 122,813.38 RMB in the same period of 2023[24] - The company reported investment losses of (50,473,598.71) RMB in the first three quarters of 2024, a decline from investment income of 71,754,545.48 RMB in the same period of 2023[23] - The company incurred asset impairment losses of (10,101,389.63) RMB in the first three quarters of 2024, a significant decrease from (786,743,942.29) RMB in the same period of 2023[23] - The average return on equity increased by 2.52 percentage points for the reporting period[10] - The weighted average return on net assets was 0.06%, an increase of 2.52 percentage points from the previous year[5]

Financial Performance - The company's revenue for Q3 2024 reached ¥263,646,520.16, representing a year-over-year increase of 76.09%[2] - Net profit attributable to shareholders for Q3 2024 was ¥2,964,467.27, while the net loss for the year-to-date period was ¥222,409,418.57, a significant reduction in loss compared to the previous year[2][5] - The company achieved a sales revenue of ¥516,153,650.93 from its meningococcal vaccine, marking a year-over-year growth of 39.07%[5] - Total operating revenue for the first three quarters of 2024 reached CNY 567,077,966.63, a significant increase from CNY 175,631,799.90 in the same period of 2023, representing a growth of approximately 223%[13] - The net loss for the first three quarters of 2024 was CNY 227,196,536.24, compared to a net loss of CNY 1,454,919,925.84 in the same period of 2023, showing an improvement of approximately 84%[14] - The company reported a comprehensive loss of CNY -226,815,781.51 for the third quarter of 2024, compared to a comprehensive loss of CNY -1,454,797,112.46 in the same quarter of 2023[15] Research and Development - Research and development (R&D) expenses totaled ¥107,918,795.43 in Q3 2024, accounting for 40.93% of revenue, a decrease of 52.89 percentage points year-over-year[3][6] - Research and development expenses for the first three quarters of 2024 were CNY 272,272,224.71, down from CNY 461,673,523.32 in 2023, reflecting a decrease of about 41%[13] - The company has focused on cost reduction and efficiency improvements, leading to a significant decrease in management and R&D expenses[5] Assets and Liabilities - The total assets of the company as of the end of Q3 2024 were ¥7,989,566,970.77, down 14.26% from the previous year[3] - Total current assets as of September 30, 2024, amounted to CNY 4,369,254,431.78, a decrease of 15.6% from CNY 5,180,827,776.61 as of December 31, 2023[10] - Total non-current assets decreased to CNY 3,620,312,538.99 from CNY 4,137,941,596.05, a decline of 12.5%[11] - Total liabilities decreased to CNY 2,926,151,613.50 from CNY 4,031,354,058.75 year-over-year, a reduction of approximately 27%[12] - Total liabilities decreased to CNY 1,172,000,000.00 from CNY 1,500,000,000.00, indicating a reduction of 21.9%[11] - The total equity attributable to shareholders of the parent company was CNY 5,063,415,357.27, down from CNY 5,274,604,094.18 in the previous year, a decline of about 4%[12] Cash Flow - The company reported a cash flow from operating activities of -¥287,414,483.35 for the year-to-date period, a decrease in net outflow of 61.63% compared to the previous year[6] - In the first three quarters of 2024, the cash inflow from operating activities was approximately CNY 609.95 million, a slight decrease from CNY 615.81 million in the same period of 2023[16] - The net cash outflow from operating activities for the first three quarters of 2024 was CNY -287.41 million, compared to CNY -748.97 million in the first three quarters of 2023, indicating an improvement[17] - Total cash outflow for operating activities in the first three quarters of 2024 was CNY 897.37 million, down from CNY 1.36 billion in 2023, indicating improved cash management[17] - The ending cash and cash equivalents balance as of the third quarter of 2024 was CNY 868.93 million, a significant decrease from CNY 2.35 billion at the end of the third quarter of 2023[18] Future Outlook - The company is focusing on new product development and market expansion strategies to enhance future growth prospects[10] - Future outlook includes continued investment in R&D and potential market expansion strategies to enhance revenue growth and operational efficiency[12]

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本通告全部 或任何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責任。 CanSino Biologics Inc. （股份代號：6185） 董事長 董事會會議通告 香港，2024年10月16日 康 希 諾 生 物 股 份 公 司（「本公司」）董 事（「董 事」）會（「董事會」）謹 此 宣 佈，董 事 會 會 議將於2024年10月29日（星 期 二）舉 行，藉 以（其 中 包 括）考 慮 及 批 准 本 公 司 及 其 附 屬公司截至2024年9月30日止九個月的第三季度業績及其發佈。 承董事會命 康希諾生物股份公司 康希諾生物股份公司 Xuefeng YU （於中華人民共和國註冊成立的股份有限公司） 於本通告日期，董事會包括執行董事Xuefeng YU博士、Shou Bai CHAO博士及王靖 女士；非執行董事李志成先生；以及獨立非執行董事桂水發先生、劉建忠先生及 張耀樑先生。 ...

证券代码：688185 证券简称：康希诺 公告编号：2024-046 康希诺生物股份公司 公司的重组脊髓灰质炎疫苗已在澳大利亚开展 I 期临床试验，详见公司于 2024 年 1 月 16 日在上海证券交易所网站（www.sse.com.cn）披露的《自愿披露 关于重组脊髓灰质炎疫苗于澳大利亚启动I期临床试验并完成首例受试者入组的 公告》（公告编号：2024-001）。 二、 临床试验相关情况 重组脊髓灰质炎疫苗开展的 I/II期临床试验拟进一步评价其在特定年龄婴幼 儿中接种后的安全性和免疫原性。 自愿披露关于重组脊髓灰质炎疫苗 于印度尼西亚获得临床试验批准的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 康希诺生物股份公司（以下简称"公司"）开发的重组脊髓灰质炎疫苗于近 日获得印度尼西亚食品药品监督管理局（Badan Pengawas Obat dan Makanan, Republik Indonesia, "BPOM"）签发的临床试验批准。 一、 产品基本情况 公司基于病毒样颗粒（virus-like parti ...

证券代码：688185 证券简称：康希诺 公告编号：2024-045 康希诺生物股份公司 重组脊髓灰质炎疫苗基于公司的蛋白结构设计和 VLP 组装技术开发，是一 种非传染性脊髓灰质炎疫苗，在生产过程中不依赖活病毒，预期具有良好的安全 性和免疫原性。非传染性的 VLP 技术路线脊髓灰质炎疫苗被世界卫生组织推荐 作为未来消灭脊髓灰质炎的首选疫苗之一，有望为全球根除脊髓灰质炎作出贡 献。同时，该候选疫苗也可成为联合疫苗的组成部分，加入联合疫苗将有利于更 广泛地推广，从而消灭脊髓灰质炎。 自愿披露关于签署重组脊髓灰质炎疫苗 及相关联合疫苗项目资助协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 康希诺生物股份公司（以下简称"公司"）于2023年10月与比尔及梅琳达·盖 茨基金会（以下简称"盖茨基金会"）签署了关于重组脊髓灰质炎疫苗的项目资 助协议 。具 体内 容 详见公 司于 2023年10月25 日在 上海 证券 交易所 网站 （www.sse.com.cn）披露的《自愿披露关于与比尔及梅琳达·盖茨基金会签署重 组脊髓 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: 2024年9月30日 | | --- | | 狀態: 新提交 | 致：香港交易及結算所有限公司 公司名稱: 康希諾生物股份公司 呈交日期: 2024年10月7日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06185 | 說明 | H 股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 132,670,900 | RMB | | 1 | RMB | | 132,670,900 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 132,670,900 | RMB | | 1 | RMB | | 132, ...

证券代码：688185 证券简称：康希诺 编号：2024-009 康希诺生物股份公司 投资者关系活动记录表 | --- | --- | --- | |------------|----------------------------|--------------------------------------------------------------| | | □ | 特定对象调研 □分析师会议 | | 投资者关系 | □ 媒体采访 √业绩说明会 | | | 活动类别 | □ 新闻发布会 | □路演活动 | | | □ 现场参观 | √其他（业绩交流会、 IR 电话等） | | | Citi Private Bank | 、 New China Asset Management 、 Sapere | | 参与单位名 | Capital、Trumed | 、富安达基金、工银瑞信、国寿养老、华安基金、汇 | | 称及人员姓 | | 添富基金、金鹰基金、开思基金、凯石投资、明汯投资、农银汇理、 | | 名 | | 融通基金、申万菱信基金、天弘基金、正心谷资本、中国人保、中 | | | 银资管等约 60 | 名 ...